Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 2Carcinoma, Hepatocellular 2Sarcoma 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Adenocarcinoma Of Esophagus 1Acrocephalosyndactylia 1

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × brivanib × Clear all
NCT04395612 2021-05-21

CQGOG0101

Chongqing University Cancer Hospital

Phase 2 Unknown
38 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡